Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02296684 · ClinicalTrials.gov registry record · Phase 2
Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma
A Phase 2 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
NCT02296684: Completed Phase 2 study, sponsored by Washington University School of Medicine.
NCT02296684 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 67 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02296684, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
Study Summary
The goal of this trial is to test the ability of MK-3475 (pembrolizumab) to improve locoregional recurrence and distant metastatic rates in high-risk patients with locally advanced head and neck squamous cell carcinomas (HNSCCs) that are treated with current standard of care surgical approaches.
Primary Outcome
-The percentage of participants who developed local-regional recurrence within one year of surgery
Interventions
- DRUG Cisplatin
- PROCEDURE Surgery
- RADIATION Intensity modulated radiation therapy
- BIOLOGICAL MK-3475 (neoadjuvant)
- RADIATION Image-guided radiation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2015-03-25 |
| Est. Completion | 2025-07-21 |
| Phase | Phase 2 |
What the finished NCT02296684 record still lists
NCT02296684 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 67 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 5 interventions - of which Cisplatin is the first listed.
NCT02296684 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02296684 about?
NCT02296684 is a clinical study titled "Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma". The goal of this trial is to test the ability of MK-3475 (pembrolizumab) to improve locoregional recurrence and distant metastatic rates in high-risk patients with locally advanced head and neck squamous cell carcinomas (HNSCCs) that are treated with current standard of care surgical approaches.
What is the current status of trial NCT02296684?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2015-03-25. Estimated completion is 2025-07-21.
What interventions are being tested in trial NCT02296684?
The interventions under investigation include: Cisplatin (DRUG), Surgery (PROCEDURE), Intensity modulated radiation therapy (RADIATION), MK-3475 (neoadjuvant) (BIOLOGICAL), Image-guided radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT02296684?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02296684's enrollment target sits among peer trials
67 974th of 2000 higher than 1,026 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI